These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 23129464)

  • 41. Standardization of Prothrombin Time/International Normalized Ratio (PT/INR).
    Dorgalaleh A; Favaloro EJ; Bahraini M; Rad F
    Int J Lab Hematol; 2021 Feb; 43(1):21-28. PubMed ID: 32979036
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Telavancin: the long and winding road from discovery to food and drug administration approvals and future directions.
    Wenzler E; Rodvold KA
    Clin Infect Dis; 2015 Sep; 61 Suppl 2():S38-47. PubMed ID: 26316557
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia.
    Sandrock CE; Shorr AF
    Clin Infect Dis; 2015 Sep; 61 Suppl 2():S79-86. PubMed ID: 26316561
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.
    Van Bambeke F
    Drugs; 2015 Dec; 75(18):2073-95. PubMed ID: 26603874
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A comparison of telavancin and vancomycin for treatment of methicillin-resistant Staphylococcus aureus infections: A meta-analysis.
    Liu Y; Wang J
    Int J Clin Pharmacol Ther; 2017 Nov; 55(11):839-845. PubMed ID: 28793957
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The clinical positioning of telavancin in Europe.
    Masterton R; Cornaglia G; Courvalin P; Lode HM; Rello J; Torres A
    Int J Antimicrob Agents; 2015 Mar; 45(3):213-20. PubMed ID: 25600892
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of telavancin, a lipoglycopeptide antibiotic, in experimental models of Gram-positive infection.
    Hegde SS; Janc JW
    Expert Rev Anti Infect Ther; 2014 Dec; 12(12):1463-75. PubMed ID: 25382700
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Case report: artificial elevation of prothrombin time by telavancin.
    Amanatullah DF; Lopez MJ; Gosselin RC; Gupta MC
    Clin Orthop Relat Res; 2013 Jan; 471(1):332-5. PubMed ID: 23129464
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.
    Zhanel GG; Calic D; Schweizer F; Zelenitsky S; Adam H; Lagacé-Wiens PR; Rubinstein E; Gin AS; Hoban DJ; Karlowsky JA
    Drugs; 2010 May; 70(7):859-86. PubMed ID: 20426497
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Telavancin: a novel lipoglycopeptide for serious gram-positive infections.
    Laohavaleeson S; Kuti JL; Nicolau DP
    Expert Opin Investig Drugs; 2007 Mar; 16(3):347-57. PubMed ID: 17302529
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Telavancin: a new lipoglycopeptide with multiple mechanisms of action.
    Kanafani ZA
    Expert Rev Anti Infect Ther; 2006 Oct; 4(5):743-9. PubMed ID: 17140351
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of telavancin in the treatment of MRSA infections in hospital.
    Bassetti M; Mikulska M; Righi E; Nicolini L; Viscoli C
    Expert Opin Investig Drugs; 2009 Apr; 18(4):521-9. PubMed ID: 19335280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]     [New Search]
    of 3.